Baker Bros. Advisors LP Stoke Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 4,633,838 shares of STOK stock, worth $161 Million. This represents 0.53% of its overall portfolio holdings.
Number of Shares
4,633,838
Previous 4,633,838
-0.0%
Holding current value
$161 Million
Previous $30.8 Million
70.68%
% of portfolio
0.53%
Previous 0.37%
Shares
9 transactions
Others Institutions Holding STOK
# of Institutions
142Shares Held
57MCall Options Held
2.7KPut Options Held
57.4K-
Black Rock Inc. New York, NY5.41MShares$187 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$187 Million18.16% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$178 Million0.89% of portfolio
-
Redmile Group, LLC San Francisco, CA4.38MShares$152 Million6.04% of portfolio
-
Morgan Stanley New York, NY3.57MShares$124 Million0.0% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $1.37B
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...